Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like Nestle Emerges as the Frontrunner for Merck KGaA's $5B Consumer Health Biz January 9, 2018 Scientists Use Graphene To Power 'Electronic Skin' That Can Feel, University of Glasgow Study Reveals March 22, 2017 GlaxoSmithKline Poaches New CSO From Google's Calico November 8, 2017
Scientists Use Graphene To Power 'Electronic Skin' That Can Feel, University of Glasgow Study Reveals March 22, 2017
